Loading clinical trials...
Loading clinical trials...
The Development of Artificial Intelligence-assisted Glaucoma Screening Program
This study will develop an artificial intelligence (AI) program for the screening of glaucoma.
We have realized that the glaucomatous optic neuropathy is irreversible. But if early detection and early intervention can be performed to control the development of the disease, it can greatly reduce the blindness rate of glaucoma, improve the life quality and physiological and mental health of patients, and alleviate the social burden. Therefore, screening and early diagnosis of glaucoma is the focus of glaucoma prevention. China has a population of 1.3 billion, which greatly increase the difficulty of disease screening. In recent years, the intersection of artificial intelligence (AI) technology and modern medicine has made efficient and rapid disease screening possible.
Age
All ages
Sex
ALL
Healthy Volunteers
Yes
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Start Date
October 1, 2018
Primary Completion Date
October 1, 2020
Completion Date
October 30, 2021
Last Updated
September 25, 2018
8,000
ESTIMATED participants
Fundus Image
DIAGNOSTIC_TEST
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03624361